Jeffrey Finer
Fondatore presso Septerna, Inc.
Provenienza dei contatti di primo grado di Jeffrey Finer
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.
78
| Private Company | Investment Managers | 78 |
| Public Company | Pharmaceuticals: Major | 20 | |
| Public Company | Pharmaceuticals: Major | 19 | |
| Subsidiary | Biotechnology | 15 | |
Ambys Medicines, Inc.
 Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Strateos, Inc.
 Strateos, Inc. Medical SpecialtiesHealth Technology Strateos engages in the automation of chemistry, biology, and tissue analysis into closed loop robotic laboratories that support drug discovery programs. The company is headquartered in the Menlo Park, CA.
5
| Holding Company | Medical Specialties | 5 |
Septerna, Inc.
 Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Transcriptic, Inc.
 Transcriptic, Inc. Medical SpecialtiesHealth Technology Transcriptic, Inc. engages in the conversion of biology into an information technology, driven by data, and computation. It specializes in biology, automation, and software engineering. The company was founded by Max Joseph Hodak on February 14, 2012 and is headquartered in Menlo Park, CA.
2
| Subsidiary | Medical Specialties | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jeffrey Finer tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Director of Finance/CFO Corporate Officer/Principal Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Stanford University | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| BLUEBIRD BIO, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal Graduate Degree Corporate Officer/Principal Doctorate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Undergraduate Degree Graduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| NEON THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer Founder | |
| INNOVIVA, INC. | Pharmaceuticals: Major | General Counsel Chief Operating Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| University of California, Berkeley | College/University | Graduate Degree Masters Business Admin Undergraduate Degree Doctorate Degree Doctorate Degree | |
| JOUNCE THERAPEUTICS, INC. | Miscellaneous Commercial Services | Chairman Chief Tech/Sci/R&D Officer Corporate Officer/Principal Director/Board Member Chief Executive Officer | |
| CONSTELLATION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member President Chief Tech/Sci/R&D Officer Chief Executive Officer Director/Board Member | |
| VOYAGER THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Director/Board Member Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Director/Board Member Undergraduate Degree Undergraduate Degree Graduate Degree Doctorate Degree | |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer. | Biotechnology | Chairman Private Equity Investor Founder Director/Board Member Consultant / Advisor | |
| Massachusetts Institute of Technology | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Undergraduate Degree | |
| REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal | |
| FOUNDATION MEDICINE INC | Medical/Nursing Services | Director/Board Member Director/Board Member Chief Executive Officer Human Resources Officer | |
| The Johns Hopkins University | College/University | Graduate Degree Director/Board Member Doctorate Degree Graduate Degree | |
| University of Pennsylvania | College/University | Graduate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree | |
| The Trustees of Columbia University in The City of New York | College/University | Corporate Officer/Principal Graduate Degree Masters Business Admin Undergraduate Degree | |
Tango Therapeutics Sub, Inc.
 Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Chairman Director/Board Member Director/Board Member Chief Executive Officer | |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Chairman Director/Board Member Consultant / Advisor | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Chairman Director/Board Member Director/Board Member Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| PLIANT THERAPEUTICS, INC. | Biotechnology | Chairman Director/Board Member Director/Board Member Director/Board Member | |
California Life Sciences Association
 California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Chairman Founder Corporate Officer/Principal | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree | |
| DECIBEL THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Director/Board Member Director/Board Member | |
| Brandeis University | College/University | Corporate Officer/Principal Graduate Degree Undergraduate Degree | |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Thrive Earlier Detection Corp.
 Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
Warp Drive Bio, Inc.
 Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Director/Board Member | |
Rapport Therapeutics, Inc.
 Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA. | Biotechnology | Founder Director/Board Member Director/Board Member | |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Biotechnology | Comptroller/Controller/Auditor Corporate Officer/Principal Corporate Officer/Principal | |
| Tufts University | College/University | Corporate Officer/Principal Corporate Officer/Principal Undergraduate Degree | |
| FULCRUM THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Rheos Medicines, Inc.
 Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
| Boston College | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree | |
| Boston University | College/University | Doctorate Degree Graduate Degree Corporate Officer/Principal | |
| NURIX THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Asher Biotherapeutics, Inc.
 Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Consultant / Advisor | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Treasurer Corporate Officer/Principal Corporate Officer/Principal | |
| Kellogg School of Management | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
MOMA Therapeutics, Inc.
 MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Chief Operating Officer Chief Executive Officer | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Private Equity Investor | |
Casma Therapeutics, Inc.
 Casma Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Casma Therapeutics, Inc. operates biotechnology company harnessing natural cellular process of autophagy to design new medicines. The company was founded by Cary Pfeffer and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Founder Founder Founder |
Statistiche
Distribuzione geografica
| Stati Uniti | 50 |
| Svizzera | 2 |
Settori
| Health Technology | 28 |
| Consumer Services | 16 |
| Commercial Services | 7 |
| Finance | 2 |
| Health Services | 2 |
Posizioni
| Director/Board Member | 510 |
| Corporate Officer/Principal | 256 |
| Independent Dir/Board Member | 158 |
| Chairman | 102 |
| Chief Executive Officer | 82 |
Contatti più connessi
| Insiders | |
|---|---|
| Mara Aspinall | 41 |
| Franklin Berger | 41 |
| Steven Paul | 39 |
| Perry Karsen | 38 |
| Neil Exter | 33 |
| Eran Broshy | 29 |
| Charles Homcy | 28 |
| Stephen Sherwin | 26 |
| Mark Levin | 26 |
| Mary Lynne Hedley | 25 |
| Alexis Borisy | 25 |
| James Geraghty | 25 |
| Robert Tepper | 24 |
| Abbie Celniker | 23 |
| Dean Mitchell | 22 |
- Borsa valori
- Insiders
- Jeffrey Finer
- Connessioni Società